Senvelgo - Oral Solution

Velagliflozin oral SGLT2 inhibitor for diabetes mellitus in cats; lowers blood glucose via glucosuria. SGLT2 inhibitor (velagliflozin) for cats. Mechanism: selectively inhibits sodium-glucose cotransporter 2 in renal proximal tubule → prevents renal glucose reabsorption → glucosuria → blood glucose reduction insulin-independently. Approved in EU/some markets for feline DM. Oral solution once daily. Key information Velagliflozin — SGLT2 inhibitor for equine insulin dysregulation. Oral daily dosing. Monitor for hypotension and electrolyte changes. Ensure adequate water access.

Oral solution (cats): administer once daily using calibrated syringe onto wet food. Administer with food to reduce GI adverse effects. Store at room temperature; protect from light. If a dose is missed Administer as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and resume the normal schedule. Never double up doses to make up for a missed one.

Genitourinary infections (UTI, mycotic). DKA risk in insulin-deficient patients. Polyuria, polydipsia. GI: vomiting, diarrhea. Hypoglycemia (concurrent insulin use). Monitor closely for ketoacidosis.

For animals Cats only. Contraindicated in DKA, renal disease, recurrent UTI. Monitor blood/urine glucose closely. Not approved for use in food-producing animals. For people handling this medication Wash hands thoroughly with soap and water after handling. Avoid contact with eyes; if contact occurs, flush with water for 15 minutes and seek medical attention. Keep out of reach of children. If accidental ingestion occurs, contact Poison Control (1-800-222-1222). SGLT2 inhibitor — Wash hands thoroughly with soap and water after handling. after handling. Keep out of reach of children.

Contact your veterinarian. SGLT2 inhibitor overdose causes dehydration and electrolyte changes. Ensure water access.